Typhoid fever continues to be important causes of illness and death, particularly among children and adolescents in south-central and Southeast Asia, where enteric fever is associated with poor sanitation and unsafe food and water. High-quality incidence data from Asia are underpinning efforts to expand access to typhoid vaccines. Efforts are underway to develop vaccines that are immunogenic in infants after a single dose and that can be produced locally in countries of endemicity. Antimicrobial resistance has sequentially emerged to traditional first-line drugs, fluoroquinolones, and third-generation cephalosporins, posing patient treatment challenges. The Vi conjugate typhoid vaccine, Typbar-TCV under clinical trial have been found to be highly immunogenic in infants and children less than 2 years of age in which unconjugated Vi polysaccharide typhoid vaccine is known to induce very low or nil immunogenic response.

Early Immunizations not only prevent mortality and morbidity but also reduce the expenditure of public and private resources. Introduction of Typhoid vaccine with measles vaccine at 9 months of age in routine EPI programs will not substantially interfere with measles elimination programs and will eliminate the need of an additional typhoid vaccination visit in the already clustered initial EPI Immunization visits. The current study proposed to evaluate immunogenicity and safety when co-administered with measles vaccine. The objective is to determine whether TCV can be successfully co-administered with Measles without interfering with the immune response to each of these antigens.

This open labeled, randomized, parallel study to evaluate the non- interference in immune response of one dose of Typhoid Vi Capsular Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) administered to children at 9 months, to measles vaccine given concomitantly.

The subjects will be screened for eligibility in to the study after obtaining written informed consent from the subject. Screening period might last for 7 days. Screening includes obtaining medical history, physical examination, demographic details (weight, height & gender), Vital signs (Heart rate, respiratory rate, body temperature-oral or axillary) and clinical evaluations.

After completion of the screening process, the eligible, subjects shall be enrolled into the study groups. Subjects shall be observed for 30 minutes after vaccination, and for the next 7 days, recorded in the subject diary cards.